Copyright 2015 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.
Cancer cells of some patients develop secondary-resistant mutations. Using cell lines created from patients’ lung cancer tumors that had become resistant to therapy, a Massachusetts General Hospital–led team has developed a model for testing drugs against hard-to-treat malignancies (Crystal AS et al. Science. doi:10.1126/science.1254721 [published online November 13, 2014]).
The strategy involved screening cancer cell lines against a panel of 76 compounds, which were tested both alone and in combination with the first-line drug therapy to which the tumor had become resistant.
Hampton T. Model Reveals Drug Combinations to Overcome Resistant Cancers. JAMA. 2015;313(1):20. doi:10.1001/jama.2014.17623
Customize your JAMA Network experience by selecting one or more topics from the list below.